ClinicalTrials.gg
RecruitingNCT07624786PVA-detectionUpdated Aug 13, 2026

Patient-Ventilator Asynchrony: Occurence and Clinical Impact in Usual Care

An observational study in Mechanical Ventilation and Patient-Ventilator Asynchrony, sponsored by Erasmus Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Erasmus Medical Center · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
110
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to unravel the occurence, impact and relations of Patient-Ventilator Aynchrony (PVA) in mechanically ventilated patients. The main questions it aims to answer are:

  • How often does PVA occur?
  • What are relations between clinical characteristics and PVA occurence?
  • What are relations between PVA occurence and patient outcomes?

All questions will be assessed using data collected during the whole course of mechanical ventilation. Mechanically ventilated patients' medical data will be re-used. PVAs will be automatically classified on ventilator waveform data, using validated Deep Breath software.

Read the detailed description

Many ventilated patients show excessive breathing efforts and abnormal, irregular breathing. This patient-ventilator asynchrony (PVA) is associated with serious discomfort, lung injury, sleep disruption and higher mortality. PVA exists in many forms and is reported in 10-90% of patients, but identifying and resolving it is challenging, even for expert clinicians. Hence, PVA prevalence and impact is likely highly underestimated, and the direct causal link with worse outcomes is inconclusive. PVAs should be better dettected, understood and resovled to optimize the individual patient's treatment.

In a previous study, the investigators validated an AI-based algorithm capable of reliable PVA detection (Deep Breath software). In this study, the investigators will apply this algorithm to the collected ventilator waveform data (offline processing), in order to reliably assess PVA occurrence, and its relation with clinical outcomes and patient characteristics in current clinical care. Data of minimally 110 patients collected over the whole course of mechanical ventilation will be assessed. Patients will be included in three ICUs to promote generalizability.

The primary outcome will be the asynchrony index (in total and per PVA type) over time. Secondary outcomes will include, but are not limited to: clinical characteristics (e.g. respiratory and hemodynamic parameters, sedation), (ICU) mortality, ventilator free days at day 28 and 90, duration of ventilation, weaning success and reintubation rate.

02

Conditions studied

  • Mechanical Ventilation
  • Patient-Ventilator Asynchrony

Keywords

  • asynchrony
  • Patient-ventilator asynchrony
  • dyssynchrony
  • Patient-ventilator interaction
  • mechanical ventilation
  • AI
  • algorithm
  • classification algorithm
  • ICU
  • Artificial intelligence
03

In context

Patient-Ventilator Asynchrony

24 studies on the registry are indexed under Patient-Ventilator Asynchrony; 11 are open to participants now.

This study's planned enrollment of 110 is above the median of 40 across 13 observational studies indexed under Patient-Ventilator Asynchrony.

Browse Patient-Ventilator Asynchrony studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients admitted to the ICU that receive invasive mechanical ventilation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years old.
  • Recordings available of ventilator waveforms synchronized with the patient's electronic health record during invasive mechanical ventilation.
  • Duration of mechanical ventilation of at least 24 hours.

Exclusion criteria

Exclusion Criteria:

  • (Previous) registered objection of patient and/or relatives to re-use clinical data for research purposes
  • No consent for re-use of data for research
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
110 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Adult patients admitted to the ICU that receive invasive mechanical ventilation

    Patients need to be \>18 years old, receive mechanical ventilation for at least 24 hours and have recordings available of ventilator waveforms, synchronized with the patient's electronic health record, during invasive mechanical ventilation.

    Other: PVA classification software

Interventions

  • OtherPVA classification software

    Patients will receive standard care, without an intervention. Data will be captured as part of standard care and analyzed for PVAs retrospectively, using dedicated offline software.

06

What researchers measure

Primary outcomes

  1. Asynchrony index over time (aggregated and per PVA type)

    Measure of how much asynchrony occurs and at what time. This measure will be calculated for all PVA types together, as well as per PVA type. The investigators calculate this over time, to see when asynchrony occurs, as well as in total, to get a global PVA prevalence measure (over the whole duration of ventilation).

    Time frame: 28 days

Secondary outcomes

  1. Use of sedatives (cumulative dose and type)

    Time frame: 28 days

  2. Mechanical ventilation settings

    Time frame: 28 days

  3. Respiratory parameters

    Time frame: 28 days

  4. Hemodynamic parameters

    Time frame: 28 days

  5. Relevant medication

    e.g. vasoactive agents, delirium related medication, analgesics

    Time frame: 28 days

  6. Use of assist devices

    e.g. dialysis, pacemaker, ventricular assist device, ECMO

    Time frame: 28 days

  7. Gas exchange parameters

    e.g. P/F ratio, PaO2, PaCO2, pH, bicarbonate

    Time frame: 28 days

  8. Blood inflammatory biomarkers

    upon availability in the patient's electronic chart, e.g. CRP, lactate

    Time frame: 28 days

  9. Sedation depth

    Richmond Agitation-Sedation Scale (RASS-score). This score ranges from -5 to +4, where a more positive score indicates more agitation.

    Time frame: 28 days

  10. Reported delirium

    Reported delirium, observed via the Delirium Observation Screening (DOS), or the Intensive Care Delirium Screening Checklist (ICDSC), depending on the standard of care of the participating center. The DOS ranges from 0-13, with a score ≥3 indicating delirium. The ICDSC ranges from 0-8, with 0-3 indicating absence of delirium and a score of ≥4 inidicating delirium.

    Time frame: 28 days

  11. Illness severity score (SOFA-score)

    SOFA-score. This score ranges from 0-24, with increasing scores reflecting more abnormal physiology and biochemistry or an increasing degree of intervention.

    Time frame: 28 days

  12. ICU mortality

    Mortality during ICU stay

    Time frame: 90 days

  13. Mortality at day 28

    Mortality at day 28

    Time frame: 28 days

  14. Mortality at day 90

    Mortality at day 90

    Time frame: 90 days

  15. Duration of ventilation

    Duration of ventilation in hours or days

    Time frame: 28 days

  16. Ventilator free days (at day 28)

    Number of ventilator free days at day 28

    Time frame: 28 days

  17. Ventilator free days (at day 90)

    Number of ventilator free days at day 90

    Time frame: 90 days

  18. Reintubation rate

    Number of times reintubation occured, reported as % of patients needing reintubation.

    Time frame: 28 days

  19. Weaning success

    Weaning success rate (%), defined as seven consecutive days without ventilator support

    Time frame: 28 days

  20. ICU length of stay

    Length of ICU stay, measured in days

    Time frame: 28 days

  21. Complications

    Complications (e.g. ventilator associated pneumonia and ICU acquired weakness) as reported in the patient file.

    Time frame: 28 days

07

Study locations

2 of 3 sites recruiting
  • Catharina Ziekenhuis Eindhoven (CZE)
    Eindhoven, North Brabant 5623EJ, Netherlands
    Recruiting
  • Leiden University Medical Center (LUMC)
    Leiden, South Holland 2333ZA, Netherlands
    Not yet recruiting
    • Bram Schoe, PhD · Contacta.schoe@lumc.nl
    • Bram Schoe, PhD · Principal investigator
    • Thijs Rietveld, MSc · Sub investigator
  • Erasmus Medical Center (EMC)
    Rotterdam, South Holland 3015GD, Netherlands
    Recruiting
    • Annemijn Jonkman, PhD · Contacta.jonkman@erasmusmc.nl · +3110-7035142
    • Annemijn Jonkman, PhD · Principal investigator
    • Thijs P Rietveld, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The final dataset will be available on reasonable request, with removed/anonymized timestamps for pseudonimization. The request will be reviewed by the PI, depending on the topic/quality of the proposal and including a plan for publication/authorship, and ensuring that the request meets legal and organizational requirements. Sharing of data for reuse by third parties will always only involve de-identified datasets and via a data transfer agreement.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: IPD will be available after publication of the Clinical Study Report. IPD will be available for 10 years, in compliance with Dutch laws.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Jun 3, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07624786
Collaborators
Deep Breath, Catharina Ziekenhuis Eindhoven, Leiden University Medical Center
Responsible party
Annemijn Jonkman (Associate professor, Principal Investigator, Erasmus Medical Center) — Principal investigator
First posted
Jun 3, 2026
Start date
Jul 21, 2026
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Annemijn Jonkman, PhD
Contact
a.jonkman@erasmusmc.nl
+3110-7035142

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion